Acute myeloid leukemias

Question 1

Core binding factor AML

Answer 1

The “good” prognostic category for AML

Classically inv(16)/t(16;16)

These patients generally do not require bone marrow transplant.

The gene causes constitutive expression of a core binding factor-like protein that sequesters RUNX1, preventing hematologic differentiation past a certain point.

Question 2

Evolution of AML therapy

Answer 2

Question 3

Therapeutic classification of AML

Answer 3

Question 4

FLT3-ITD burden

Answer 4

In other words, how many tandem duplications and how many duplications are in a tandem duplication?

Classically stratified by two factors:
allelic ratio – above or below 50%
and length – above or below 70 bp

Question 5

Allelic ratio

Answer 5

AUC of FLT3-ITD / AUC WT FLT3

AUC = area under curve